Nyxoah (NYXH) to Release Quarterly Earnings on Thursday

Nyxoah (NASDAQ:NYXH) is expected to release its Q4 2025 results after the market closes on Thursday, March 19th. Analysts expect Nyxoah to post earnings of ($0.65) per share and revenue of $5.70 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:30 PM ET.

Nyxoah Trading Up 0.3%

NYXH opened at $3.15 on Tuesday. The firm’s fifty day moving average is $4.48 and its two-hundred day moving average is $4.91. The firm has a market cap of $107.29 million, a PE ratio of -1.27 and a beta of 1.56. Nyxoah has a twelve month low of $3.08 and a twelve month high of $11.87. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.41 and a current ratio of 1.70.

Institutional Investors Weigh In On Nyxoah

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its stake in shares of Nyxoah by 72.4% during the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after buying an additional 3,303 shares during the last quarter. Raymond James Financial Inc. increased its position in shares of Nyxoah by 35.6% in the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock valued at $59,000 after acquiring an additional 3,353 shares during the last quarter. Deutsche Bank AG increased its position in shares of Nyxoah by 40.0% in the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after acquiring an additional 10,000 shares during the last quarter. Citadel Advisors LLC bought a new stake in Nyxoah during the third quarter worth about $98,000. Finally, Shay Capital LLC bought a new stake in Nyxoah during the second quarter worth about $374,000.

Analysts Set New Price Targets

NYXH has been the subject of a number of recent analyst reports. Cantor Fitzgerald upgraded shares of Nyxoah to a “strong-buy” rating in a research report on Wednesday, March 4th. Stifel Nicolaus reduced their target price on Nyxoah from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, January 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nyxoah in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.